Khaled Musallam: de-LIGHT Study on Use of Lifetime Anemia and Iron Control Index (LAICI) in Thalassemia Treatment
Khaled Musallam, Group Chief Research Officer Burjeel Holdings, Adj. Prof. Khalifa University and Weill Cornell Medicine (NY), shared on LinkedIn:
”Pleased to share results from our de-LIGHT study out now in the British Journal of Haematology. What makes this data special and what’s its added value:
- Most studies evaluating the impact of anemia and iron overload on morbidity and mortality outcomes in beta-thalassemia (including those from our group) used spot indices or followed patients over short or defined periods of time. In de-LIGHT, it took tremendous effort but we were able to capture a lifetime observation since diagnosis looking at anemia/iron vs outcomes over a median follow up of 38 years in 500+ patients
- We defined patients as having NTDT or TDT based on lifetime exposure to transfusions (rather than their status ‘now’ or in the past 6 months)
- We used a lifetime anemia and iron control index (LAICI) defined based on adherence to TIF guidelines recommendations in NTDT and TDT. This was significantly and independently associated with overall survival and incidence of various morbidities.
Thalassemia treatment is lifelong, and evidence-based, optimal management of anemia and iron overload should persist over the entire disease course and cannot be sporadic.”
Read the full article here.
Article: Impact of lifetime anaemia and iron control on outcomes in β-thalassaemia: Data from the longitudinal de-LIGHT study
Authors: Khaled Musallam, Angela Vitrano, Alessandro Inzerillo, Rosario Di Maggio, Rita Barone, Antonino Giangreco, Maria Concetta Renda, Emanuela Fecarotta, Antonio Troia, Antonino Giambona, Giovan Battista Ruffo, Efthymia Vlachaki, Theodora M. Venou, Paolo Ricchi, Brunella Ziello, Marilena Serra, Elena Colizzi, Filomena Longo, Martina Culcasi, Aurelio Maggio
Stay updated on the latest scientific advances in the field of hematology with Hemostasis Today.
-
Oct 21, 2025, 06:59Samwel Mikaye: Polycythemia and the Risk of Blood Clots
-
Oct 21, 2025, 06:58Samuel Nweke: Interpreting D-Dimer Results
-
Oct 21, 2025, 05:20Ewa Fiorentino Rozek: APS - When “Unprovoked” Clots And Pregnancy Loss Connect
-
Oct 21, 2025, 03:503 Questions With Abigail Ajanel Gomez – Touch Haematology Future Leader 2025
-
Oct 21, 2025, 01:57Mohamed Reda: Clotting Factors — The Key Players in Blood Coagulation
-
Oct 21, 2025, 11:13Hanny Al Samkari's Commentary on Iron Deficiency Anemia in Inherited Bleeding Disorders
-
Oct 21, 2025, 11:08Wolfgang Miesbach on New Real-World Data for Haemophilia B Prophylaxis
-
Oct 21, 2025, 06:53Haitham Shedeed: The Importance of Heparin Testing Before Catheterization
-
Oct 21, 2025, 06:44Asmaa A About Pseudo Thrombocytopenia: Causes and How to Handle
-
Oct 21, 2025, 06:41Natural Anticoagulants in Focus․ Protein C and S
-
Oct 21, 2025, 06:58Arno Nierich: How Caffeine Affects Red Blood Cells and Blood Storage
-
Oct 21, 2025, 06:43Could Gene Therapy Offer Lasting Quality of Life for People with Hemophilia B?
-
Oct 21, 2025, 06:18Katerina Akassoglou Receives Zenith Fellows Award to Advance Alzheimer’s Research
-
Oct 16, 2025, 06:07ClearPlasma - A New Breakthrough in Stopping Life-Threatening Bleeds
-
Oct 14, 2025, 05:26Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
-
Oct 21, 2025, 11:11Nana Kwame Kwabi Boateng: Grateful For The Opportunity to Serve As A SEARCH Ambassador
-
Oct 21, 2025, 05:00Sheila Cristina Ouriques Martins Is Grateful to Be Among The Legends Who Changed The Reality of Stroke Worldwide
-
Oct 21, 2025, 01:47Cathy Bliem: Yesterday, I Made My 4th Plasma Donation of 2025...
-
Oct 20, 2025, 12:40Asfand Yar Cheema: Honored to be featured in Video Journal of Hematology and Hematological Oncology
-
Oct 20, 2025, 12:25Laurent Bertoletti Highlights Evolving Role of Anticoagulation in Pulmonary Hypertension Treatment